In this study, we evaluated the association between the selected biomarkers: Vit D, IL-13, and miRNA-135a, and treatment outcome of HCV with DAAs and the risk of development of HCC in Egyptian HCV-infected patients who received DAA therapy in the form of “sofosbuvir and daclatasvir ± ribavirin”. Here, IL13 is linked to hepatocellular carcinoma.